You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾(688185.SH):嬰幼兒組分百白破疫苗DTcP正在進行三期臨牀啟動前的準備工作
格隆匯 08-04 07:21

格隆匯8月4日丨康希諾(688185.SH)近期在接待機構投資者調研時表示,十三價肺炎球菌結合疫苗PCV13i在完成III期臨牀現場工作後,持續進行血清檢測及數據的收集分析,當完成統計分析及總結報吿後,會盡快組織申報材料啟動新藥註冊申請流程。對於III期臨牀的數據表現,如有階段性分析成果,會與市場分享。

嬰幼兒組分百白破疫苗DTcP正在進行三期臨牀啟動前的準備工作,包括對照苗採購、臨牀現場考察等,公司將加快推進該產品的研發。同時,該疫苗也是組分百白破聯合疫苗進一步研發的基礎,組分百白破疫苗產品組合將進一步豐富公司產品策略,提升公司核心競爭力。

重組肺炎蛋白疫苗PBPV的Ib期臨牀推進順利,已完成入組,也在持續開展臨牀樣本的檢測工作。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account